Typically, these are motivated by a conspicuous success, a development program that was driven by the strength of beautiful molecular data, and the canonical example these days is PCSK9, a target which seems to feature an almost unprecedented alignment of human genetics, biomarker, and animal model data.

FORBES: Strategy: Why Big Pharmas Do What They Do -- And How Silicon Valley Might Help Them Think Differently